PRESCRIPTION PATTERN OF ANTI HYPERTENSIVE DRUGS IN SHRI SATHYA SAI MEDICAL COLLEGE & RESEARCH INSTITUTE

Size: px
Start display at page:

Download "PRESCRIPTION PATTERN OF ANTI HYPERTENSIVE DRUGS IN SHRI SATHYA SAI MEDICAL COLLEGE & RESEARCH INSTITUTE"

Transcription

1 Original Article PRESCRIPTION PATTERN OF ANTI HYPERTENSIVE DRUGS IN SHRI SATHYA SAI MEDICAL COLLEGE & RESEARCH INSTITUTE Annamalai Maduram 1, Harikrishna 2 INTRODUCTION High blood pressure, termed "hypertension," is a condition that afflicts almost 1 billion people worldwide and is a leading cause of morbidity and mortality. Therefore, this disease is sometimes called the "silent killer." This disease is usually asymptomatic until the damaging effects of hypertension (such as stroke, myocardial infarction, renal dysfunction, visual problems, etc.) are observed. Hypertension is a major risk factor for coronary artery disease, myocardial infarction ("heart attacks") and stroke.1from the estimated prevalence of hypertension would increase from 26.4% in 2 to 29.2% in Drug prescription pattern studies which evaluate and analyze the drug therapy in hypertension and hypertension associated with DM is very essential from time to time to observe the prescribing attitude of physicians with the aim of rational use of drugs based on the WHO guidelines. Hypertension (HTN) is one of the major chronic diseases resulting in high morbidity and mortality in the world population. Prevalence of HTN in India is reported to vary from 4-15% in urban and 2-8% in rural population. Socioeconomic, behavioral, stressful lifestyle and nutritional issues of the people led to enormous increase of cardiovascular diseases. HTN and Diabetes Mellitus (DM) frequently coexist which increases with age. HTN is about twice as common in patients with DM as in those without (8%).3 REVIEW OF LITERATURE Hypertensive is defined as an abnormal elevation in diastolic pressure and/or systolic pressure; mean arterial pressure is also elevated in hypertension, but it is not usually measured in people. In past years, the diastolic value was emphasized in assessing hypertension. However, elevations in systolic pressure ("systolic hypertension") are also associated with increased incidence of coronary and cerebrovascular disease (e.g., stroke). Therefore, we now recognize that both systolic and diastolic pressure values are important to note. According to the latest U.S. national guidelines (JNC 7 Report)), the following represents different stages of hypertension: Classification Systolic (mmhg) Diastolic(mmHg) Normal <12 <8 Prehypertension Stage Stage 2 >16 > Patients with primary hypertension are generally treated with drugs that 1) reduce blood volume (which reduces central venous pressure and cardiac output), 2) reduce systemic vascular resistance, or 3) reduce cardiac output by depressing heart rate and stroke volume. Many antihypertensive drugs have their primary action on systemic vascular resistance. Some of these drugs produce vasodilation by interfering with sympathetic adrenergic vascular tone (sympatholytics) or by blocking the formation of angiotensin II or its vascular receptors. Other drugs are direct arterial dilators, and some are mixed arterial and venous dilators. Although less commonly used because of a high incidence of side effects, there are drugs that act on regions in the brain that control sympathetic autonomic outflow. By reducing sympathetic efferent activity, centrally acting drugs decrease arterial pressure by decreasing systemic vascular resistance and cardiac output. Some antihypertensive drugs, most notably betablockers, depress heart rate and contractility (this 68

2 Annamalai Maduram et al; Prescription Pattern of Anti decreases stroke volume) by blocking the influence of sympathetic nerves on the heart. Calcium-channel blockers, especially those that are more cardioselective, also reduce cardiac output by decreasing heart rate and contractility. Some calcium-channel blockers (most notably the dihydropyridines) are more selective for the systemic vasculature and therefore reduce 1 systemic vascular resistance. The Classes of drugs used in the treatment of 1 hypertension are listed below. Diuretics like Thiazide diuretics, loop diuretics, potassium-sparing diuretics Vasodilators like (alpha-blockers), Angiotensin converting enzyme inhibitors (ACE inhibitors),angiotensin receptor blockers (ARBs), calcium-channel blockers, Direct acting arterial dilators, ganglionic blockers, nitro dilators, Potassiumchannel openers, Reni inhibitors. Cardioinhibitory drugs like Beta-blockers, Calciumchannel blockers centrally acting sympatholytics. Summary of antihypertensive drug treatment. 4 Aged under 65 Alpha-adrenoceptor antagonists Aged over 65 Year or *2. CCB is preferred but consider a thiazide-like diuretic if a CCB is not tolerated or the person has oedema, evidence of heart failure or a high risk of heart failure. *3 Consider a low dose of spironolactone15 or higher doses of a thiazide-like diuretic. *4 At the time of publication (August 211), spironolactone did not have a UK marketing authorization for this indication. Informed consent should be obtained and documented. *5 Consider an alpha- or beta-blocker if further diuretic therapy is not tolerated, or is contraindicated or ineffective. AIM & OBJECTIVE: To evaluate drug utilization in hypertensive s and gain knowledge of existing prescription patterns in the treatment of diagnosed hypertension can provide useful information for improving clinical practice in this field. The aims of this study are to describe current treatment practices and to summarize different treatment practices of Shri Sathya Sai Medical College and Research Institute, medical outpatient department patterns and time trends for antihypertensive medication USE OF SELECTION INDICATORS To know the percent of male and female patient number and percent of various groups of drugs. Step 1 A C Percentage of utilization of different categories antihypertensive drugs. Percentage of antihypertensive drugs in combination with other category drugs. Percentage of combination of antihypertensive Step 2 A+ C Key A- drugs Percentage of co added drugs Step 3 A + C + D receptor *1 C Calcium To describe the current treatment practice in Shri Sathya Sai Medical College and Research Step 4 A + C + D * 3, 4 or alph * 5 *2 D- Institute. Drug selection indicators selected for present study includes 5 Ratio of male and female patients, *1. Choose a low-cost ARB 69

3 Annamalai Maduram et al; Prescription Pattern of Anti The prevalence of age group OBSERVATIONS & RESULTS Percentage of one/two drug combination, Types of dosage forms, The total % of utilization of different categories of antihypertensive drugs The % of antihypertensive drugs in combination with other category drugs. MATERIAL AND METHODS This was a cross-sectional observational study done in the outpatient department of Shri Sathya Sai Medical College and Research Institute, from March to April 212 for duration of two months a total of 466 prescriptions were collected from outpatient medicine department according the Performa given by WHO based prescription Audit format. From which the A total of 466 prescriptions for essential hypertension were studied. The major findings of our studies are discussed below. Age group of 61-7 (125). Less number of patients with age group of 81 9 years 6 patients Demographic profile of the study population was found to be the age group from 19-9 years. The distribution of age as given in the graph below (Fig 1) higher number of patients under the 61-7 age groups 71-8 age 61-7 age Form no. : PRESCRIPTION AUDIT PERFORMA Patient name.... Age... Sex Address 51-6 age 41-5 age 31-4 age 2-3 age Department: medicine IPD / OPD No Diagnosis / Provisional Diagnosis / Symptoms: Sr. No. Drug Name Dose Duration Gender Sex had been relevant factor in the clinical representation of hypertension out of 466 patients 284 were s and 182were s Signature of Data Collector 15 data s such as age, sex, address diagnosis and prescribed drug route of drug administration, dose, duration, single drug, combination of drug used were collected from the prescription and written in the 5 Performa form attached above. 7

4 Annamalai Maduram et al; Prescription Pattern of Anti Co- morbidities: A Total of 236 patients had one or more concurrent diseases including Diabetes Millets (114), Asthma (11) and CHF (2) and Hypothyroid (6).Statins and Aspirin were also used for the treatment of hypertension (2%). Drug treatment The patients with asthma and diabetes millets were commonly prescribed either Enalapril or Amlodipine. Only two patients on Beta blocker (Atenolol) Whereas 9 patients were on Atenolol and Amlodipine therapy. the number of patients receiving single drug were 314(67%) among which were 173(55%) and were 14 (45%). The highly prescribed single drug was Amlodipine 42% followed by Enalapril of 16%, Atenolol of 8% with 1% of each verapamil, Propranolol and Metoprolol. In the Medicine department the maximum no patient used Amlodipine at dose of 5mg for seven day and advised to come after seven day for a follow up. The next higher no of patient used enalapril of 2.5mg dose for seven day. Commonly the drugs were given once a day. single Drug Amylodipin Enalapril single drug the number of patients receiving Two drugs combinations were 139(3%) among which were 95(68%) and were 44 (32%). The highly prescribed combinations of drug were Amlodipine and Enalapril of 74% of which female were 68(66%) male were 35(34%) followed by the drug combination of Amlodipine and Atenolol of 16 (12%)with 14 female and 2 males with the other combination of just 1% of each combination as follows Amlodipine and Lasix, Enalapril and Lasix Enalapril and Atenolol, Enalapril and verapamil, Amlodipine and Propranolol and Amlodipine and Metoprolol. Fig: Triple drugs combination: the number of patients receiving three drugs combinations were 6(1%) among which were 1 and were 5. The drugs prescribed in combinations were Amlodipine, Enalapril and Atenolol or Nifedipine or Lasix or Metoprolol and the other combination of Atenolol and Lasix, Enalapril or Metoprolol. DISCUSSION The present study reveal that higher numbers of patient belongs to the age group of (61-7years) the drug used in this age are appropriate to the guidelines. The study finding clearly indicate that hypertension was higher in female(61%)than male(39%).from this study we found that out of 466 patients. 236 patients has one or more concurrent diseases like Diabetes Milletswere14%, Asthma 2 %, CHF. 4% and Hypothyroid 1%. The presence of concurrent diseases could influence the choice of antihypertensive drugs. The patients with Asthma 71

5 Annamalai Maduram et al; Prescription Pattern of Anti and Diabetes Millets commonly received either Enalapril or Amlodipine. Sixty seven percent of total hypertensive patients received single drugs like Amlodipine (42%), Enalapril (16%), Atenolol (8%) and 1% of patients received Verapamil or Propranolol and Metoprolol. Thirty percent of patients on two drugs treatment the drugs are Amlodipine and Enalapril (24%) followed by Amlodipine and Atenolol (12%).One percent of patients on treatment with any one of the combinations, Amlodipine + Lasix, Enalapril + Verapamil, Amlodipine + Propranolol and Amlodipine + Metoprolol. From this study we found that calcium channel blocker commonly followed ACE inhibition. One percent of patients on 3 drugs treatments. The combinations were used are Amlodipine+ Enalapril +Atenolol or Nifedipine. CONCLUSION This study showed that most of outpatients with hypertension in Shri Sathya Sai Medical College and Research Institute, medical outpatient department received monotherapy we also found that the most frequently used class of antihypertensive drugs were the calcium channel blocker and angiotensin converting enzyme inhibitors. This was in accordance of WHO guidance. ACKNOWLEDGEMENT I would like to thank the HOD and staff of Department of medicine Shri Sathya Sai Medical College and Research Institute, for providing us the valuable data for this study. My sincere thanks to my guide for guiding me to do this study. I also would like thank the Hospital staff, the technical support given by the technician of department of pharmacology and patients for the kind cooperation during this study. The lost but not the least I would like to thank the ICMR for giving me an opportunity to this study. REFERENCE 1. Richard E. Klabunde PhD, Text book of Cardiovascular Physiology Concepts, 2nd edition, Published by Lippincott Williams & Wilkins, Kearney PM; Whelton M; Reynolds K;Munter P;Whelton PK; He J.Global burden hypertension: analysis of worldwide data.lancet.,25, McInnis NH, Fodor G, Lum-Kwong MM, Leenen FH. Antihypertensive medication use and blood pressure control: a community-based crosssectional survey (ON-BP). University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Am J Hypertens. 28 Nov; 21(11): Epub 28 Sep cited on 1/8/ Ansari K.U, Singh.S, Pandey R.C. Evaluation of prescribing patterns of doctors for rational Drug therapy, IndianJ.Pharmacol 1998:3: Annamalai Maduram 2. Harikrishna Professor, Shri Sathya Sai Medical College and Research Institute, Chennai. Asst. Professor, Shri Sathya Sai Medical College and Research Institute, Chennai. 72

Study of the Side effects profile of different antihypertensive drugs among the Hypertensive patient

Study of the Side effects profile of different antihypertensive drugs among the Hypertensive patient Study of the Side effects profile of different antihypertensive drugs among the Hypertensive patient Shrestha RK 1, Khan GM 1, Thapa P 1, Koju R 2 1 Department of Pharmacy, Kathmandu University 2 Department

More information

JMSCR Vol 05 Issue 03 Page March 2017

JMSCR Vol 05 Issue 03 Page March 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.219 Comparative Study of Adverse Effect of

More information

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)

More information

Synopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets

Synopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study

More information

Proceedings of the 36th World Small Animal Veterinary Congress WSAVA

Proceedings of the 36th World Small Animal Veterinary Congress WSAVA www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amodip 1.25 mg chewable tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Active substance:

More information

AMLODIPINE BESYLATE + OLMESARTAN MEDOXOMIL. Dihydropyridine Ca channel blocker [Dhp-CCB] + Angiotensin II receptor blockage [ARB]

AMLODIPINE BESYLATE + OLMESARTAN MEDOXOMIL. Dihydropyridine Ca channel blocker [Dhp-CCB] + Angiotensin II receptor blockage [ARB] AMLODIPINE BESYLATE + OLMESARTAN MEDOXOMIL Dihydropyridine Ca channel blocker [Dhp-CCB] + Angiotensin II receptor blockage [ARB] ESH/ESC HT MANAGEMENT GUIDELINE 2013 DIAGNOSIS TARGET BP TARGET BP CONTROL

More information

Assessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT,

Assessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT, Assessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT, Sylva LU SCHWAGER, Edward D STURROCK, Lubbe WIESNER, Brian

More information

New Zealand Data Sheet. Apo-Amlodipine

New Zealand Data Sheet. Apo-Amlodipine New Zealand Data Sheet Apo-Amlodipine Presentation APO-AMLODIPINE 2.5mg are white to off-white, round unscored tablets, engraved APO on one side and AML over 2.5 on the other side. Each tablet typically

More information

IJBCP International Journal of Basic & Clinical Pharmacology. Adverse drug effects monitoring of amlodipine in a tertiary care hospital

IJBCP International Journal of Basic & Clinical Pharmacology. Adverse drug effects monitoring of amlodipine in a tertiary care hospital Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20182069 Original Research Article Adverse drug

More information

Fortekor 5 mg. Tablets for Dogs and Cats

Fortekor 5 mg. Tablets for Dogs and Cats Date: 9 April 2003 Page: 1 of 7 Carton, main panel PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Info pest Verified Fortekor 5 mg Tablets for Dogs and Cats Active Constituent:

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Sun, 10 Mar 2019 06:52:14 GMT) CTRI Number Last Modified On 29/07/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

Antihypertensive efficacy of amlodipine in children with chronic kidney diseases

Antihypertensive efficacy of amlodipine in children with chronic kidney diseases (2001) 15, 387 391 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Antihypertensive efficacy of amlodipine in children with chronic kidney diseases

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 January 2008

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 January 2008 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 January 2008 ZANIDIP 10mg, film-coated tablets B/28 (CIP: 347 638.7) B/30 (CIP: 372 259.6) B/90 (CIP: 372 260.4)

More information

Public Assessment Report Scientific discussion. Perindopril tert-butylamine/amlodipine Stada (perindopril and amlodipine) SE/H/1500/01-04/DC

Public Assessment Report Scientific discussion. Perindopril tert-butylamine/amlodipine Stada (perindopril and amlodipine) SE/H/1500/01-04/DC Public Assessment Report Scientific discussion Perindopril tert-butylamine/amlodipine Stada (perindopril and amlodipine) SE/H/1500/01-04/DC This module reflects the scientific discussion for the approval

More information

1 INDICATIONS AND USAGE. 1.1 Hypertension FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE. 1.1 Hypertension FULL PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMLODIPINE besylate tablets USP safely and effectively. See full prescribing information for AMLODIPINE

More information

The 4 th Generation calcium channel blocker C I L N I D I P I N E

The 4 th Generation calcium channel blocker C I L N I D I P I N E T The 4 th Generation calcium channel blocker C I L N I D I P I N E = TOp DUal Action New Ca 2+ Channel Blocker Cilnidipine (IHS) - C 27 H 28 N 2 O 7 INDICATION Essential Hypertension DOSAGE & PACKAGE

More information

COST VARIATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS AVAILABLE IN INDIAN MARKET: AN ECONOMIC PERSPECTIVE

COST VARIATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS AVAILABLE IN INDIAN MARKET: AN ECONOMIC PERSPECTIVE IJPSR (2016), Vol. 7, Issue 5 (Research Article) Received on 03 December, 2015; received in revised form, 14 January, 2016; accepted, 07 February, 2016; published 01 May, 2016 COST VARIATION ANALYSIS OF

More information

APO-AMLODIPINE/ATORVASTATIN 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40 & 10/80 TABLETS

APO-AMLODIPINE/ATORVASTATIN 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40 & 10/80 TABLETS APO-AMLODIPINE/ATORVASTATIN 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40 & 10/80 TABLETS NAME OF THE MEDICINE Amlodipine (as besylate) and Atorvastatin (as calcium propylene glycol solvate) Active Ingredient

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers

More information

Dosage equivalent lisinopril amlodipine

Dosage equivalent lisinopril amlodipine Dosage equivalent 09/22/2017 Sons massage goes to far vol 2 09/23/2017 Integer game printable 09/25/2017 -Senior night invitation for parents -Games for anger management teenagers 09/26/2017 Minecraft

More information

Original Article. Introduction. Korean Circulation Journal

Original Article. Introduction. Korean Circulation Journal Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Valsartan 160 mg/amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate

More information

PATIENT INFORMATION LEAFLET ACCEL-AMLODIPINE. Amlodipine Tablets 5 mg and 10 mg amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent

PATIENT INFORMATION LEAFLET ACCEL-AMLODIPINE. Amlodipine Tablets 5 mg and 10 mg amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent PATIENT INFORMATION LEAFLET Pr ACCEL-AMLODIPINE Amlodipine Tablets 5 mg and 10 mg amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent ACTION AND CLINICAL PHARMACOLOGY ACCEL-AMLODIPINE

More information

Tolerance and safety of enalapril

Tolerance and safety of enalapril Br. J. clin. Pharmac. (1984), 18, 249S-253S Tolerance and safety of enalapril W. McFATE SMITH, R. 0. DAVIES, M. A. GABRIEL, D. M. KRAMSCH, F. MONCLOA, JANET E. RUSH & J. F. WALKER Merck Sharp & Dohme Research

More information

Nursing intervention for amlodipine

Nursing intervention for amlodipine Nursing intervention for amlodipine Amlodipine is a calcium channel blocking agent that selectively blocks calcium ion reflux across cell membranes of cardiac and vascular smooth muscle without. PHYSICAL

More information

NAME OF THE MEDICINE. PRODUCT INFORMATION Cadivast Amlodipine (as besilate) and atorvastatin (as calcium trihydrate) tablets

NAME OF THE MEDICINE. PRODUCT INFORMATION Cadivast Amlodipine (as besilate) and atorvastatin (as calcium trihydrate) tablets PRODUCT INFORMATION Cadivast Amlodipine (as besilate) and atorvastatin (as calcium trihydrate) tablets NAME OF THE MEDICINE The active ingredients in Cadivast are amlodipine besilate and atorvastatin calcium

More information

Page 1 of 21. Tablets: 2.5 mg, 5 mg, and 10 mg (3)

Page 1 of 21. Tablets: 2.5 mg, 5 mg, and 10 mg (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMLODIPINE BESYLATE TABLETS safely and effectively. See full prescribing information for AMLODIPINE

More information

SUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats

SUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE

More information

DRUG INTERACTIONS

DRUG INTERACTIONS HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMLODIPINE BESYLATE TABLETS safely and effectively. See full prescribing information for AMLODIPINE

More information

CHEMMART AMLODIPINE 2.5 mg, 5 mg, 10 mg TABLETS

CHEMMART AMLODIPINE 2.5 mg, 5 mg, 10 mg TABLETS CHEMMART AMLODIPINE 2.5 mg, 5 mg, 10 mg TABLETS Product Information Australia NAME OF THE MEDICINE Amlodipine besylate. DESCRIPTION Amlodipine besylate is a dihydropyridine derivative. Chemical Name: 3-ethyl

More information

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine 5 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg Amlodipine as Amlodipine Besilate. For full

More information

Norvasc 5 & 10mg tablets

Norvasc 5 & 10mg tablets Norvasc 5 & 10mg tablets 1. Name of the medicinal product Norvasc 5& 10 mg Tablets 2. Qualitative and quantitative composition Each tablet contains amlodipine besilate equivalent to 5 and 10mg amlodipine.

More information

Frequently asked questions

Frequently asked questions Frequently asked questions At what stage of heart failure should Cardalis be used? Cardalis should be given as part of your standard heart failure therapy as soon as clinical signs (such as exercise intolerance,

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Istolde 10 mg tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 10 mg tablets: Each tablet contains 10 mg amlodipine (as besilate) For

More information

Maximum antihypertensive effects are attained within 2 weeks after a change in dose. AZOR may be administered with other antihypertensive agents.

Maximum antihypertensive effects are attained within 2 weeks after a change in dose. AZOR may be administered with other antihypertensive agents. Page 4 FULL PRESCRIBING INFORMATION AZOR (amlodipine and olmesartan medoxomil) tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine 10 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg Amlodipine as Amlodipine Besilate. For

More information

NL/H/-882/ SUMMARY OF PRODUCT CHARACTERISTICS 1/13

NL/H/-882/ SUMMARY OF PRODUCT CHARACTERISTICS 1/13 SUMMARY OF PRODUCT CHARACTERISTICS 1/13 1 NAME OF THE MEDICINAL PRODUCT Amlodipine CT 5 mg, tabletten Amlodipine CT 10 mg, tabletten 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Amlodipine ratiopharm tablets

More information

C o n v e r s i b e n a z e p r. l i s i n o p r

C o n v e r s i b e n a z e p r. l i s i n o p r C o n v e r s i b e n a z e p r t o l i s i n o p r Ace-inhibitor conversions. Common Medication Conversions (Equivalents) Ace Inhibitors : Drug Comparisons - Home Page. Hydrochlorothiazide; lisinopril

More information

Dexmedetomidine. Dr.G.K.Kumar,M.D.,D.A., Assistant Professor, Madras medical college,chennai. History

Dexmedetomidine. Dr.G.K.Kumar,M.D.,D.A., Assistant Professor, Madras medical college,chennai. History Dexmedetomidine Dr.G.K.Kumar,M.D.,D.A., Assistant Professor, Madras medical college,chennai Dexmedetomidine is the most recently released IV anesthetic. It is a highly selective α 2 -adrenergic agonist

More information

One Amlodipine KRKA 5 mg or 10 mg tablet contains amlodipine maleate equivalent to either 5 mg or 10 mg amlodipine per tablet.

One Amlodipine KRKA 5 mg or 10 mg tablet contains amlodipine maleate equivalent to either 5 mg or 10 mg amlodipine per tablet. 1. NAME OF THE MEDICINAL PRODUCT Amlodipine KRKA 5 mg tablets Amlodipine KRKA 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One Amlodipine KRKA 5 mg or 10 mg tablet contains amlodipine maleate

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET NEW ZEALAND DATA SHEET 1. PRODUCT NAME NORVASC 5 mg and 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 mg coated tablet contains amlodipine besilate equivalent to 5 mg amlodipine. Each

More information

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pimovita 10 mg chewable tablets for dogs Pimovita vet.10 mg chewable tablets for

More information

Dual retard tablets of amlodipine besylate and atenolol

Dual retard tablets of amlodipine besylate and atenolol 10 Formulation, optimization and evaluation of dual retard tablet of amlodipine besylate and atenolol Hypertension, commonly referred to as high blood pressure, is a medical condition where the pressure

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg tablets for dogs Cardalis 5 mg/40 mg tablets for dogs Cardalis 10 mg/80 mg tablets for dogs

More information

AUSTRALIAN PRODUCT INFORMATION AMLO (AMLODIPINE BESILATE) UNCOATED TABLETS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

AUSTRALIAN PRODUCT INFORMATION AMLO (AMLODIPINE BESILATE) UNCOATED TABLETS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION AUSTRALIAN PRODUCT INFORMATION AMLO (AMLODIPINE BESILATE) UNCOATED TABLETS 1 NAME OF THE MEDICINE Amlodipine besilate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION AMLO contains the active ingredient Amlodipine

More information

NL/H/880/01-02 FINAL SMPC

NL/H/880/01-02 FINAL SMPC SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine ratiopharm tablets 5 mg, tablets Amlodipine ratiopharm tablets 10 mg, tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Consultation with stakeholders - Reassessment of reimbursement status for dihydropyridine calcium channel blockers - ATC group C08CA

Consultation with stakeholders - Reassessment of reimbursement status for dihydropyridine calcium channel blockers - ATC group C08CA Company Consultation with stakeholders - Reassessment of reimbursement status for dihydropyridine calcium channel blockers - ATC group C08CA The Danish Medicines Agency has assessed the question of the

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg chewable tablets for dogs Cardalis 5 mg/40 mg chewable tablets for dogs Cardalis 10 mg/80

More information

Reminder to Pharmacists. Issuance of Bulletin #58

Reminder to Pharmacists. Issuance of Bulletin #58 Corporate and Provincial Program Support 300 Carlton, Winnipeg MB R3B 3M9 www.manitoba.ca/health Reminder to Pharmacists Issuance of Bulletin #58 Bulletin #58, effective April 29, 2008, completes the initial

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Amlodipine Bluefish 5 mg tablets Amlodipine Bluefish 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains

More information

SANDOZ AMLODIPINE PRODUCT MONOGRAPH. Amlodipine Besylate. Tablets 2.5 mg, 5 mg and 10 mg. Antihypertensive-Antianginal Agent

SANDOZ AMLODIPINE PRODUCT MONOGRAPH. Amlodipine Besylate. Tablets 2.5 mg, 5 mg and 10 mg. Antihypertensive-Antianginal Agent PRODUCT MONOGRAPH Pr SANDOZ AMLODIPINE Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg Antihypertensive-Antianginal Agent Sandoz Canada Inc. Date of Revision: 145 Jules Léger December 1, 2017 Boucherville,

More information

Public Assessment Report Scientific discussion

Public Assessment Report Scientific discussion Public Assessment Report Scientific discussion SE/H/1397/01-05/DC Ramipril/Amlodipine Sandoz (ramipril/amlodipine) Applicant: Sandoz A/S This module reflects the scientific discussion for the approval

More information

AMLODIPINE BESILATE / ATORVASTATIN CALCIUM

AMLODIPINE BESILATE / ATORVASTATIN CALCIUM 1. THERAPEUTIC CATEGORY Calcium Channel Blocker Lipid Regulating Agent AMLODIPINE BESILATE / ATORVASTATIN CALCIUM NORVASC PROTECT 2. FORMULATION Amlodipine besilate/atorvastatin calcium (Norvasc Protect)

More information

JGIM ORIGINAL ARTICLE

JGIM ORIGINAL ARTICLE JGIM ORIGINAL ARTICLE Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment

More information

PRODUCT MONOGRAPH. amlodipine besylate. Tablets 2.5, 5 and 10 mg. Antihypertensive-Antianginal Agent

PRODUCT MONOGRAPH. amlodipine besylate. Tablets 2.5, 5 and 10 mg. Antihypertensive-Antianginal Agent PRODUCT MONOGRAPH Pr NORVASC amlodipine besylate Tablets 2.5, 5 and 10 mg Antihypertensive-Antianginal Agent PFIZER CANADA INC. 17 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Revision: September

More information

FORMULATION AND EVALUATION OF S-(-)-AMLODIPINE BESYLATE AND NEBIVOLOL HYDROCHLORIDE TABLETS

FORMULATION AND EVALUATION OF S-(-)-AMLODIPINE BESYLATE AND NEBIVOLOL HYDROCHLORIDE TABLETS Digest Journal of Nanomaterials and Biostructures Vol. 5, No 1, March 2010, p. 201 205 FORMULATION AND EVALUATION OF S-(-)-AMLODIPINE BESYLATE AND NEBIVOLOL HYDROCHLORIDE TABLETS S. A. SHAIKH *, S. S.

More information

Other Available Assistance Programs Angiotensin Receptor Blocker (ARB)

Other Available Assistance Programs Angiotensin Receptor Blocker (ARB) BENICAR 20 MG TABS (olmesartan) Angiotensin Receptor Blocker (ARB) Daiichi Sankyo Open Care Program These are the best alternatives for Benicar in terms of similarity of medication: EDARBI MG TABS (azilsartan)

More information

SAMPLE. Certificate in Understanding the Safe Handling of Medication in Health and Social Care PRESCRIPTION. Workbook 1 LEGISLATION.

SAMPLE. Certificate in Understanding the Safe Handling of Medication in Health and Social Care PRESCRIPTION. Workbook 1 LEGISLATION. NCFE Level 2 Certificate in Understanding the Safe Handling of Medication in Health and Social Care ACCOUNTABILITY PRESCRIPTION ADMINISTRATION STORAGE SUPPLY LEGISLATION 1 LCG 2015 This section will introduce

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Amlotan 5 and 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Amlotan 5 mg tablets: Each tablet contains 5 mg amlodipine (as

More information

PRODUCT MONOGRAPH SANDOZ AMLODIPINE. Amlodipine Besylate. Tablets 2.5 mg, 5 mg and 10 mg. Antihypertensive-Antianginal Agent

PRODUCT MONOGRAPH SANDOZ AMLODIPINE. Amlodipine Besylate. Tablets 2.5 mg, 5 mg and 10 mg. Antihypertensive-Antianginal Agent PRODUCT MONOGRAPH Pr SANDOZ AMLODIPINE Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg Antihypertensive-Antianginal Agent Sandoz Canada Inc. Date of Revision: 145 Jules Léger September 25, 2015 Boucherville,

More information

Gang LING, Ai-jun LIU, Fu-ming SHEN, Guo-jun CAI, Jian-guo LIU, Ding-feng SU 2

Gang LING, Ai-jun LIU, Fu-ming SHEN, Guo-jun CAI, Jian-guo LIU, Ding-feng SU 2 Acta Pharmacol Sin 2007 Nov; 28 (11): 1755 1760 Full-length article Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously

More information

PRODUCT MONOGRAPH. Pr AMLODIPINE. Amlodipine Besylate Tablets, House Standard. 5 mg and 10 mg. Amlodipine (as amlodipine besylate)

PRODUCT MONOGRAPH. Pr AMLODIPINE. Amlodipine Besylate Tablets, House Standard. 5 mg and 10 mg. Amlodipine (as amlodipine besylate) PRODUCT MONOGRAPH Pr AMLODIPINE Amlodipine Besylate Tablets, House Standard 5 mg and 10 mg Amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent JAMP Pharma Corporation Date of Preparation:

More information

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption. A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE CARTON BOX AND LABELS OF 100 ml and 250 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT TILKOMAY 300 mg/ml + 90 mg/ml solution

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Dormilan solution for injection for dogs and cats [FR] Dormilan 1 mg/ml solution for injection for dogs and cats [DE, ES,

More information

Antimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS

Antimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives

More information

PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine with Viekirax or Viekira Pak

PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine with Viekirax or Viekira Pak PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine with Viekirax or Viekira Pak Dwaipayan Mukherjee, Ph.D. Jiuhong Zha, Ph.D. Rajeev Menon, Ph.D. Mohamad Shebley, Ph.D. Clinical

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FORTEKOR PLUS 1.25 mg/2.5 mg tablets for dogs FORTEKOR PLUS 5 mg/10 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE

More information

Prof. Dr Manjushree Mohanty : Prof. Dr K P Tripathy : Dr Sougata Sarkar : Dr Vartika Srivastava

Prof. Dr Manjushree Mohanty : Prof. Dr K P Tripathy : Dr Sougata Sarkar : Dr Vartika Srivastava IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 3 Ver. VI (Mar. 2016), PP 24-34 www.iosrjournals.org Comparative Analysis On Incidence Of Pedal

More information

DATE OF QUALIFICATION BASE TELEPHONE NUMBER ADDRESS. CLINICAL SPECIALITY/ FIELD OR SERVICE

DATE OF QUALIFICATION BASE TELEPHONE NUMBER  ADDRESS. CLINICAL SPECIALITY/ FIELD OR SERVICE Part 1 NON MEDICAL INDEPENDENT PRESCRIBING - APPROVAL TO PRACTICE FORM Wirral Community NHS Trust (Page 1 of 5) This form must be completed and brought to the Initial Prescribing Induction if not completed

More information

PRODUCT MONOGRAPH. amlodipine besylate. Tablets 2.5, 5 and 10 mg. Antihypertensive-Antianginal Agent

PRODUCT MONOGRAPH. amlodipine besylate. Tablets 2.5, 5 and 10 mg. Antihypertensive-Antianginal Agent PRODUCT MONOGRAPH Pr GD -AMLODIPINE amlodipine besylate Tablets 2.5, 5 and 10 mg Antihypertensive-Antianginal Agent GenMed, a division of Pfizer Canada Inc. 17 300 Trans-Canada Highway Kirkland, Quebec

More information

Course: NURS 6615 Semester: Spring 2003 Credits: 3 Title: Prescriptive Practice

Course: NURS 6615 Semester: Spring 2003 Credits: 3 Title: Prescriptive Practice FAIRLEIGH DICKINSON UNIVERSITY HENRY P BECTON SCHOOL OF NURSING AND ALLIED HEALTH Course: NURS 6615 Semester: Spring 2003 Credits: 3 Title: Prescriptive Practice Faculty: Lois E Brenneman, MSN, ANP, FNP,

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER [Enalapril Lercanidipine] 20 mg/10 mg film-coated tablets enalapril maleate/lercanidipine hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Read all of this

More information

Converting iv vasotec to po vasotec

Converting iv vasotec to po vasotec Converting iv vasotec to po vasotec The Borg System is 100 % Retrievable Converting iv vasotec to po vasotec Conversion from IV to oral dosage form. If not concurrently receiving diuretics, initiate enalapril

More information

Lotrel (amlodipine besylate and benazepril hydrochloride) Combination Capsules

Lotrel (amlodipine besylate and benazepril hydrochloride) Combination Capsules T2004-83 Lotrel (amlodipine besylate and benazepril hydrochloride) Combination Capsules 2.5 mg/10 mg 5 mg/10 mg 5 mg/20 mg 10 mg/20 mg Rx only Prescribing Information USE IN PREGNANCY When used in pregnancy

More information

11/17/2015. Tox Tips: How to Easily Improve Your Management of Small Animal Poisoning Cases. November 17, The best pet insurance plan ever!

11/17/2015. Tox Tips: How to Easily Improve Your Management of Small Animal Poisoning Cases. November 17, The best pet insurance plan ever! Tox Tips: How to Easily Improve Your Management of Small Animal Poisoning Cases November 17, 2015 Ahna Brutlag, DVM, MS, DABT, DABVT Associate Director of Veterinary Services Pet Poison Helpline abrutlag@petpoisonhelpline.com

More information

melatonin amlodipine generic for amlodipine benazepril amlodipine angioedema amlodipine feline amlodipine 5 mg description

melatonin amlodipine generic for amlodipine benazepril amlodipine angioedema amlodipine feline amlodipine 5 mg description Follow all directions on your computer even when amlodipine for sale you buy Ambien. Call your doctor or dial 911 immediately. Ativan can cause tolerance, physical dependence, addiction and withdrawal

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Medeson 1 mg/ml solution for injection for dogs and cats [AT, CY, CZ, DE, EL, ES, HR, IT, LT, LV, PL, PT, RO, SI, SK] Medeson,

More information

Benazepril equivalent dose of lisinopril

Benazepril equivalent dose of lisinopril Benazepril equivalent dose of lisinopril 11/25/2017 Hcpcs code j7613 not covered by medicare 11/26/2017 Pay att uverse bill over phone 11/28/2017 -Pill h5 325 -Shelby scott wbz reporter dementia 11/29/2017

More information

1.1. ACE-inhibitors and flushing

1.1. ACE-inhibitors and flushing 1.1. ACE-inhibitors and Introduction Angiotensin-converting enzyme (ACE) inhibitors are widely used for the treatment of and heart failure. The following ACE-inhibitors are registered in the Netherlands:

More information

1 of 24. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 08/2015

1 of 24. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 08/2015 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Amlodipine and Benazepril Hydrochloride Capsules, USP safely and effectively. See full prescribing

More information

PRODUCT MONOGRAPH. Amlodipine Besylate tablets. 2.5 mg, 5 mg & 10 mg (amlodipine as amlodipine besylate) Antihypertensive-Antianginal Agent

PRODUCT MONOGRAPH. Amlodipine Besylate tablets. 2.5 mg, 5 mg & 10 mg (amlodipine as amlodipine besylate) Antihypertensive-Antianginal Agent PRODUCT MONOGRAPH Pr AMLODIPINE Amlodipine Besylate tablets 2.5 mg, 5 mg & 10 mg (amlodipine as amlodipine besylate) Antihypertensive-Antianginal Agent Sivem Pharmaceuticals ULC 4705 Dobrin Street St.

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardisure flavoured 10 mg Tablets For dogs (Austria, Belgium, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands,,

More information

Jess Weidman, DVM, DACVIM- Cardiology CVCA Cardiac Care for Pets Dogwood Veterinary Emergency and Specialty

Jess Weidman, DVM, DACVIM- Cardiology CVCA Cardiac Care for Pets Dogwood Veterinary Emergency and Specialty Jess Weidman, DVM, DACVIM- Cardiology CVCA Cardiac Care for Pets Dogwood Veterinary Emergency and Specialty Diagnostics Cardiac auscultation Chest Radiographs BNP Genetic testing Case Scenarios Pre-anesthesia

More information

Drug monograph of CADUET

Drug monograph of CADUET Drug monograph of CADUET Generic name: Amlodipine and Atorvastatin Brand name: Caduet Manufacturer: Pfizer Classification: Prescription only medicine Strength (amlodipine mg/ atorvastatin mg): 2.5/10,

More information

Cats usually develop secondary hypertension with an

Cats usually develop secondary hypertension with an J Vet Intern Med 2015 Randomized Placebo-Controlled Clinical Trial of a Chewable Formulation of Amlodipine for the Treatment of Hypertension in Client-Owned Cats M. Huhtinen, G. Derre, H.J. Renoldi, M.

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LOTREL safely and effectively. See full prescribing information for LOTREL. LOTREL (amlodipine besylate

More information

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each ml contains: Tilmicosin 300 mg;

More information

LUPIN LIMITED SAFETY DATA SHEET. Section 1: Identification

LUPIN LIMITED SAFETY DATA SHEET. Section 1: Identification LUPIN LIMITED SAFETY DATA SHEET Section 1: Identification Section 1, Identification Material Manufacturer Distributor Amlodipine Besylate and Benazepril Hydrochloride Capsules 2.5 mg/10 mg, 5 mg/10 mg,

More information

Applicant Invented name Strength Pharmaceutical Form

Applicant Invented name Strength Pharmaceutical Form ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES. 1 Member State Marketing Authorisation

More information

Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen

Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen ORIGINAL RESEARCH Adherence with single-pill amlodipine/ vs a two-pill regimen Bimal V Patel 1 R Scott Leslie 1 Patrick Thiebaud 1 Michael B Nichol 2 Simon SK Tang 3 Henry Solomon 3 Dennis Honda 3 JoAnne

More information

1.3.1 Amlodipine besilate SPC, Labeling and Package Leaflet NL

1.3.1 Amlodipine besilate SPC, Labeling and Package Leaflet NL SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT 5 mg tablets 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 5 mg tablets: Each

More information

Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without

Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) OPINION FOLLOWING AN ARTICLE 29 REFERRAL. Amlovita

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) OPINION FOLLOWING AN ARTICLE 29 REFERRAL. Amlovita European Medicines Agency COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) OPINION FOLLOWING AN ARTICLE 29 REFERRAL Amlovita International Non-Proprietary Name (INN): Amlodipine BACKGROUND INFORMATION*

More information

RENT THERAPEUTIC RESEARC~ VOLUME 66, NUMBER 2, MARcH/APRIL 2005

RENT THERAPEUTIC RESEARC~ VOLUME 66, NUMBER 2, MARcH/APRIL 2005 RENT THERAPEUTIC RESEARC~ VOLUME 66, NUMBER 2, MARcH/APRIL 2005 Bioavailability Study of Fixed-Dose Tablet Versus Capsule Formulation of Amlodipine Plus Benazepril: A Randomized, Single-Dose, Two-Sequence,

More information

The Comparative analysis of different Brands of AMLODIPINE

The Comparative analysis of different Brands of AMLODIPINE International Invention of Scientific Journal ISSN: 2457-0958 Research Paper Abstract: Available Online at http://iisj.in/index.php/iisj October, 2018 Volume 02 Issue 10 The Comparative analysis of different

More information

AMLOPRESS SAJA PHARMA

AMLOPRESS SAJA PHARMA 08-15 AMLOPRESS SAJA PHARMA Amlodipine (as besylate) 5 mg Capsule for Oral Use 1. NAME OF THE MEDICINAL PRODUCT AMLOPRESS 5 mg Capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Capsule contains

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NOSEDORM 5 mg/ml Solution for injection for dogs and cats [DE, ES, FR, PT] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each

More information

Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India

Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India Human Journals Research Article April 2016 Vol.:6, Issue:1 All rights are reserved by Zarine Khety et al. Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India Keywords: Drug

More information

AMLODIPINE BESILATE NORVASC

AMLODIPINE BESILATE NORVASC AMLODIPINE BESILATE NORVASC 1.0 PHARMACOLOGIC CATEGORY Antihypertensive/Anti-Angina 2.0 DESCRIPTION Amlodipine besilate (NORVASC ) is the besilate salt of amlodipine, a long-acting calcium channel blocker.

More information